Asciminib(ABL001) , 10mMinDMSO , 1492952-76-7
CAS NO.：1492952-76-7
Empirical Formula: C20H18ClF2N5O3
Molecular Weight: 449.84
MDL number: MFCD31560488
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB719.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 631.7±55.0 °C(Predicted) |
| Density | 1.518±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO:93.0(Max Conc. mg/mL);206.74(Max Conc. mM) Ethanol:90.0(Max Conc. mg/mL);200.07(Max Conc. mM) |
| form | A crystalline solid |
| pka | 10.81±0.70(Predicted) |
| color | White to off-white |
| InChIKey | VOVZXURTCKPRDQ-CQSZACIVSA-N |
| SMILES | C1=NC(N2CC[C@@H](O)C2)=C(C2C=CNN=2)C=C1C(NC1=CC=C(OC(Cl)(F)F)C=C1)=O |
Description and Uses
Asciminib is the first-in-class Specifically Targeting the ABL1 Myristoyl Pocket (STAMP) inhibitor, which was granted accelerated approval in 2021 for patients with Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs), and for adult patients with Ph+ CML in chronic phase with the T315I mutation. Asciminib binds to a myristoyl site of the BCR-ABL1 protein and locks the protein into an inactive conformation through a mechanism distinct from those of all other orthosteric TKIs such as imatinib, thus overcoming drug resistance arising from ATPbinding site mutations. Asciminib mimics the function of the myristoylated N-terminus of ABL1 and restores the natural autoinhibition of the ABL1b protein.
Asciminib comprises ABL kinase inhibitors and/or SLC7A11 inhibitors for the treatment of cancer and central nervous system (CNS) disorders.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
